Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-10-11

AUTHORS

Keisuke Kida, Yugo Shibagaki, Naoto Tominaga, Naoki Matsumoto, Yoshihiro J. Akashi, Fumihiko Miyake, Kenjiro Kimura

ABSTRACT

Background and ObjectivesThe pharmacokinetics and pharmacodynamics of tolvaptan (7.5 or 15 mg/day) in combination with furosemide have been investigated in heart failure (HF) patients with normal kidney function but not in HF patients with advanced kidney dysfunction. This study evaluated the efficacy of tolvaptan in HF patients with advanced kidney dysfunction (estimated glomerular filtration rate <45 mL/min/1.73 m2) by conducting a pharmacokinetic and pharmacodynamic study in these patients.MethodsTolvaptan (15 mg once daily) was administered orally for 7 days in combination with furosemide (40–200 mg).ResultsThe peak plasma tolvaptan concentration and area under the plasma concentration–time curve were 379.41 ± 149.69 ng/mL and 4,657.38 ± 2,741.79 ng·h/mL, respectively, in HF patients with advanced kidney dysfunction. These values were greater in HF patients with advanced kidney dysfunction than values reported in the literature for healthy subjects and HF patients with normal kidney function. Urine volume increased and body weight decreased significantly compared with those before tolvaptan administration in HF patients with advanced kidney dysfunction.ConclusionThis study showed that adding tolvaptan to furosemide was effective in HF patients with advanced kidney dysfunction. This study also suggests that in these patients 15 mg/day of tolvaptan should be sufficient, and increasing the dose or the frequency of dosing to overcome diuretic resistance should not be necessary, and consideration should be given to using a lower dose and/or prolonging the dosing interval. More... »

PAGES

273-284

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40262-014-0194-6

DOI

http://dx.doi.org/10.1007/s40262-014-0194-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003890559

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25305049


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antidiuretic Hormone Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzazepines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diuretics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Furosemide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tolvaptan", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae, 216-8511, Kawasaki, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
            "Department of Cardiology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae, 216-8511, Kawasaki, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kida", 
        "givenName": "Keisuke", 
        "id": "sg:person.01105230756.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105230756.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shibagaki", 
        "givenName": "Yugo", 
        "id": "sg:person.01333704044.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333704044.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tominaga", 
        "givenName": "Naoto", 
        "id": "sg:person.0601015041.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601015041.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Naoki", 
        "id": "sg:person.0737732513.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737732513.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Akashi", 
        "givenName": "Yoshihiro J.", 
        "id": "sg:person.01210667766.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210667766.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyake", 
        "givenName": "Fumihiko", 
        "id": "sg:person.01300550774.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300550774.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412764.2", 
          "name": [
            "Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kimura", 
        "givenName": "Kenjiro", 
        "id": "sg:person.01031207723.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031207723.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10557-011-6299-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011130570", 
          "https://doi.org/10.1007/s10557-011-6299-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2013.147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033229856", 
          "https://doi.org/10.1038/clpt.2013.147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-012-1295-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046643185", 
          "https://doi.org/10.1007/s00228-012-1295-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10557-011-6349-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046772974", 
          "https://doi.org/10.1007/s10557-011-6349-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2013.140", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045085136", 
          "https://doi.org/10.1038/clpt.2013.140"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-10-11", 
    "datePublishedReg": "2014-10-11", 
    "description": "Background and ObjectivesThe pharmacokinetics and pharmacodynamics of tolvaptan (7.5 or 15\u00a0mg/day) in combination with furosemide have been investigated in heart failure (HF) patients with normal kidney function but not in HF patients with advanced kidney dysfunction. This study evaluated the efficacy of tolvaptan in HF patients with advanced kidney dysfunction (estimated glomerular filtration rate <45\u00a0mL/min/1.73\u00a0m2) by conducting a pharmacokinetic and pharmacodynamic study in these patients.MethodsTolvaptan (15\u00a0mg once daily) was administered orally for 7\u00a0days in combination with furosemide (40\u2013200\u00a0mg).ResultsThe peak plasma tolvaptan concentration and area under the plasma concentration\u2013time curve were 379.41\u00a0\u00b1\u00a0149.69\u00a0ng/mL and 4,657.38\u00a0\u00b1\u00a02,741.79\u00a0ng\u00b7h/mL, respectively, in HF patients with advanced kidney dysfunction. These values were greater in HF patients with advanced kidney dysfunction than values reported in the literature for healthy subjects and HF patients with normal kidney function. Urine volume increased and body weight decreased significantly compared with those before tolvaptan administration in HF patients with advanced kidney dysfunction.ConclusionThis study showed that adding tolvaptan to furosemide was effective in HF patients with advanced kidney dysfunction. This study also suggests that in these patients 15\u00a0mg/day of tolvaptan should be sufficient, and increasing the dose or the frequency of dosing to overcome diuretic resistance should not be necessary, and consideration should be given to using a lower dose and/or prolonging the dosing interval.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40262-014-0194-6", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6116599", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "54"
      }
    ], 
    "keywords": [
      "advanced kidney dysfunction", 
      "efficacy of tolvaptan", 
      "HF patients", 
      "heart failure patients", 
      "normal kidney function", 
      "kidney dysfunction", 
      "failure patients", 
      "kidney function", 
      "pharmacodynamic studies", 
      "plasma concentration-time curve", 
      "pharmacodynamics of tolvaptan", 
      "concentration-time curve", 
      "tolvaptan concentrations", 
      "tolvaptan administration", 
      "diuretic resistance", 
      "patients 15", 
      "urine volume", 
      "healthy subjects", 
      "tolvaptan", 
      "low dose", 
      "patients", 
      "body weight", 
      "dysfunction", 
      "ConclusionThis study", 
      "furosemide", 
      "dose", 
      "efficacy", 
      "days", 
      "pharmacodynamics", 
      "pharmacokinetics", 
      "study", 
      "administration", 
      "subjects", 
      "interval", 
      "combination", 
      "function", 
      "weight", 
      "background", 
      "volume", 
      "resistance", 
      "concentration", 
      "frequency", 
      "literature", 
      "values", 
      "curves", 
      "area", 
      "consideration"
    ], 
    "name": "Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study", 
    "pagination": "273-284", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003890559"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40262-014-0194-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25305049"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40262-014-0194-6", 
      "https://app.dimensions.ai/details/publication/pub.1003890559"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_626.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40262-014-0194-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40262-014-0194-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40262-014-0194-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40262-014-0194-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40262-014-0194-6'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      91 URIs      78 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40262-014-0194-6 schema:about N14d6448d52924ef78255dfe40990d28f
2 N1d596707600a40e4bb444c199e8ea382
3 N20aa9e4886a14f2292ce5db86f32b076
4 N3ca5281b22e44a53b05273735c76e492
5 N4d4a0e25d1134c8495c94392141c97da
6 N87c238a3a87d420f889770d5a31e87c4
7 N90dcad7c671f4ca0a2579b65abf6041b
8 Naeb32884cc8a4f9ca5effee8a2e2fffc
9 Nb753e2d5b34545d686d5d70f713a33a9
10 Nbff2f98accca48188c7430181679e784
11 Nd8491de844ef4db486912359637a3b9e
12 Nde1986cef77646f9afda390291c10253
13 Ne4218a06b926446a99a553586982fe41
14 Nf1d5ef4c5711406fa4728cb910bcf831
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nc7cada0712eb456481ef8cdca0a619e4
18 schema:citation sg:pub.10.1007/s00228-012-1295-5
19 sg:pub.10.1007/s10557-011-6299-3
20 sg:pub.10.1007/s10557-011-6349-x
21 sg:pub.10.1038/clpt.2013.140
22 sg:pub.10.1038/clpt.2013.147
23 schema:datePublished 2014-10-11
24 schema:datePublishedReg 2014-10-11
25 schema:description Background and ObjectivesThe pharmacokinetics and pharmacodynamics of tolvaptan (7.5 or 15 mg/day) in combination with furosemide have been investigated in heart failure (HF) patients with normal kidney function but not in HF patients with advanced kidney dysfunction. This study evaluated the efficacy of tolvaptan in HF patients with advanced kidney dysfunction (estimated glomerular filtration rate <45 mL/min/1.73 m2) by conducting a pharmacokinetic and pharmacodynamic study in these patients.MethodsTolvaptan (15 mg once daily) was administered orally for 7 days in combination with furosemide (40–200 mg).ResultsThe peak plasma tolvaptan concentration and area under the plasma concentration–time curve were 379.41 ± 149.69 ng/mL and 4,657.38 ± 2,741.79 ng·h/mL, respectively, in HF patients with advanced kidney dysfunction. These values were greater in HF patients with advanced kidney dysfunction than values reported in the literature for healthy subjects and HF patients with normal kidney function. Urine volume increased and body weight decreased significantly compared with those before tolvaptan administration in HF patients with advanced kidney dysfunction.ConclusionThis study showed that adding tolvaptan to furosemide was effective in HF patients with advanced kidney dysfunction. This study also suggests that in these patients 15 mg/day of tolvaptan should be sufficient, and increasing the dose or the frequency of dosing to overcome diuretic resistance should not be necessary, and consideration should be given to using a lower dose and/or prolonging the dosing interval.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N337b952e246447ff88e185a2281b6b5f
29 Nc7a25bb09e4743439dce981977d5f2bb
30 sg:journal.1085321
31 schema:keywords ConclusionThis study
32 HF patients
33 administration
34 advanced kidney dysfunction
35 area
36 background
37 body weight
38 combination
39 concentration
40 concentration-time curve
41 consideration
42 curves
43 days
44 diuretic resistance
45 dose
46 dysfunction
47 efficacy
48 efficacy of tolvaptan
49 failure patients
50 frequency
51 function
52 furosemide
53 healthy subjects
54 heart failure patients
55 interval
56 kidney dysfunction
57 kidney function
58 literature
59 low dose
60 normal kidney function
61 patients
62 patients 15
63 pharmacodynamic studies
64 pharmacodynamics
65 pharmacodynamics of tolvaptan
66 pharmacokinetics
67 plasma concentration-time curve
68 resistance
69 study
70 subjects
71 tolvaptan
72 tolvaptan administration
73 tolvaptan concentrations
74 urine volume
75 values
76 volume
77 weight
78 schema:name Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study
79 schema:pagination 273-284
80 schema:productId N42162756ab3f42238cceb21baaaab851
81 Nc119a5097024402bbe4e1f4339425b91
82 Ne6704a27b2114b94be24657d12828370
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003890559
84 https://doi.org/10.1007/s40262-014-0194-6
85 schema:sdDatePublished 2022-10-01T06:39
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher Nef89980b9f034856ab6caf81cc8cc856
88 schema:url https://doi.org/10.1007/s40262-014-0194-6
89 sgo:license sg:explorer/license/
90 sgo:sdDataset articles
91 rdf:type schema:ScholarlyArticle
92 N034d72dff189440d985cc9ec83412b8a rdf:first sg:person.01333704044.43
93 rdf:rest N7ebc361fa50b4dd7930e2b9066385dd3
94 N0b850e6b5c5d4ebebf4942310f210e94 rdf:first sg:person.01210667766.28
95 rdf:rest Ndd85ddc705fe49b680936d928e62aafd
96 N14d6448d52924ef78255dfe40990d28f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Diuretics
98 rdf:type schema:DefinedTerm
99 N179076bc934341f7bd8ed6cb0d643c25 rdf:first sg:person.01031207723.16
100 rdf:rest rdf:nil
101 N1d596707600a40e4bb444c199e8ea382 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antidiuretic Hormone Receptor Antagonists
103 rdf:type schema:DefinedTerm
104 N20aa9e4886a14f2292ce5db86f32b076 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Tolvaptan
106 rdf:type schema:DefinedTerm
107 N337b952e246447ff88e185a2281b6b5f schema:issueNumber 3
108 rdf:type schema:PublicationIssue
109 N3ca5281b22e44a53b05273735c76e492 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Female
111 rdf:type schema:DefinedTerm
112 N42162756ab3f42238cceb21baaaab851 schema:name doi
113 schema:value 10.1007/s40262-014-0194-6
114 rdf:type schema:PropertyValue
115 N4d4a0e25d1134c8495c94392141c97da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Male
117 rdf:type schema:DefinedTerm
118 N7ebc361fa50b4dd7930e2b9066385dd3 rdf:first sg:person.0601015041.03
119 rdf:rest Nb924924bf6cd4cab8e17674db1fe9709
120 N87c238a3a87d420f889770d5a31e87c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Adult
122 rdf:type schema:DefinedTerm
123 N90dcad7c671f4ca0a2579b65abf6041b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Aged
125 rdf:type schema:DefinedTerm
126 Naeb32884cc8a4f9ca5effee8a2e2fffc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Humans
128 rdf:type schema:DefinedTerm
129 Nb753e2d5b34545d686d5d70f713a33a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Heart Failure
131 rdf:type schema:DefinedTerm
132 Nb924924bf6cd4cab8e17674db1fe9709 rdf:first sg:person.0737732513.42
133 rdf:rest N0b850e6b5c5d4ebebf4942310f210e94
134 Nbff2f98accca48188c7430181679e784 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Aged, 80 and over
136 rdf:type schema:DefinedTerm
137 Nc119a5097024402bbe4e1f4339425b91 schema:name dimensions_id
138 schema:value pub.1003890559
139 rdf:type schema:PropertyValue
140 Nc7a25bb09e4743439dce981977d5f2bb schema:volumeNumber 54
141 rdf:type schema:PublicationVolume
142 Nc7cada0712eb456481ef8cdca0a619e4 rdf:first sg:person.01105230756.21
143 rdf:rest N034d72dff189440d985cc9ec83412b8a
144 Nd8491de844ef4db486912359637a3b9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Benzazepines
146 rdf:type schema:DefinedTerm
147 Ndd85ddc705fe49b680936d928e62aafd rdf:first sg:person.01300550774.97
148 rdf:rest N179076bc934341f7bd8ed6cb0d643c25
149 Nde1986cef77646f9afda390291c10253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Middle Aged
151 rdf:type schema:DefinedTerm
152 Ne4218a06b926446a99a553586982fe41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Furosemide
154 rdf:type schema:DefinedTerm
155 Ne6704a27b2114b94be24657d12828370 schema:name pubmed_id
156 schema:value 25305049
157 rdf:type schema:PropertyValue
158 Nef89980b9f034856ab6caf81cc8cc856 schema:name Springer Nature - SN SciGraph project
159 rdf:type schema:Organization
160 Nf1d5ef4c5711406fa4728cb910bcf831 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Kidney Diseases
162 rdf:type schema:DefinedTerm
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
167 schema:name Clinical Sciences
168 rdf:type schema:DefinedTerm
169 sg:grant.6116599 http://pending.schema.org/fundedItem sg:pub.10.1007/s40262-014-0194-6
170 rdf:type schema:MonetaryGrant
171 sg:journal.1085321 schema:issn 0312-5963
172 1179-1926
173 schema:name Clinical Pharmacokinetics
174 schema:publisher Springer Nature
175 rdf:type schema:Periodical
176 sg:person.01031207723.16 schema:affiliation grid-institutes:grid.412764.2
177 schema:familyName Kimura
178 schema:givenName Kenjiro
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031207723.16
180 rdf:type schema:Person
181 sg:person.01105230756.21 schema:affiliation grid-institutes:grid.412764.2
182 schema:familyName Kida
183 schema:givenName Keisuke
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105230756.21
185 rdf:type schema:Person
186 sg:person.01210667766.28 schema:affiliation grid-institutes:grid.412764.2
187 schema:familyName Akashi
188 schema:givenName Yoshihiro J.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210667766.28
190 rdf:type schema:Person
191 sg:person.01300550774.97 schema:affiliation grid-institutes:grid.412764.2
192 schema:familyName Miyake
193 schema:givenName Fumihiko
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300550774.97
195 rdf:type schema:Person
196 sg:person.01333704044.43 schema:affiliation grid-institutes:grid.412764.2
197 schema:familyName Shibagaki
198 schema:givenName Yugo
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333704044.43
200 rdf:type schema:Person
201 sg:person.0601015041.03 schema:affiliation grid-institutes:grid.412764.2
202 schema:familyName Tominaga
203 schema:givenName Naoto
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601015041.03
205 rdf:type schema:Person
206 sg:person.0737732513.42 schema:affiliation grid-institutes:grid.412764.2
207 schema:familyName Matsumoto
208 schema:givenName Naoki
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737732513.42
210 rdf:type schema:Person
211 sg:pub.10.1007/s00228-012-1295-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046643185
212 https://doi.org/10.1007/s00228-012-1295-5
213 rdf:type schema:CreativeWork
214 sg:pub.10.1007/s10557-011-6299-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011130570
215 https://doi.org/10.1007/s10557-011-6299-3
216 rdf:type schema:CreativeWork
217 sg:pub.10.1007/s10557-011-6349-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046772974
218 https://doi.org/10.1007/s10557-011-6349-x
219 rdf:type schema:CreativeWork
220 sg:pub.10.1038/clpt.2013.140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045085136
221 https://doi.org/10.1038/clpt.2013.140
222 rdf:type schema:CreativeWork
223 sg:pub.10.1038/clpt.2013.147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033229856
224 https://doi.org/10.1038/clpt.2013.147
225 rdf:type schema:CreativeWork
226 grid-institutes:grid.412764.2 schema:alternateName Department of Cardiology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae, 216-8511, Kawasaki, Kanagawa, Japan
227 Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan
228 Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
229 Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
230 schema:name Department of Cardiology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae, 216-8511, Kawasaki, Kanagawa, Japan
231 Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan
232 Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
233 Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
234 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...